Introduction: In this study the full sequence of the calcitonin receptor gene (CALCR) in a group of Iranian males suffering from recurrent calcium urinary stones was compared with that of a control group. Methods: Serum and urinary biochemistry related to urolithiasis were evaluated in 105 males diagnosed with recurrent kidney calcium stones and 101 age-matched healthy control males. The polymerase chain reaction single-strand conformation polymorphism method was used to detect new polymorphisms in the CALCR. Results: Nine polymorphisms were detected; seven were in the non-coding and two in the coding region. The T allele associated with the 3′UTR+18C>T polymorphism was observed exclusively in the stone formers. The exact odds ratio for the T allele in this locus for those at risk of stone formation was 36.72 (95% CI 4.95-272.0) (p < 0.001). The mean (standard deviation) urine calcium concentration was 117 (60) mg/l in patients with the C allele and 152 (72) mg/l in those with the T allele (p = 0.03). In addition, IVS1-6T>C and IVS1insA polymorphisms in intron 1 were associated with kidney stone disease (p < 0.001). Regarding single nucleotide polymorphism 447, mean (standard deviation) of serum calcitonin levels were 16.7 (18.7) pg/ml, 10.5 (11.0) pg/ml and 9.94 (9.7) pg/ml in subjects with TT, TC and CC genotypes, respectively (p = 0.01). Conclusion: Our data indicate a potential association between 3′UTR+18C>T and intron 1 polymorphisms in the CALCR and the risk of kidney stone disease.

Keywords:
Calcitonin receptor gene, Calcium urolithiasis, Etiology, Genetic association, Polymorphism, Serum calcitonin
1.
Danpure CJ: Genetic disorders and urolithiasis. Urol Clin North Am 2000;27:287-299, viii.
2.
Basiri A, Shakhssalim N, Khoshdel AR, Ghahestani SM, Basiri H: The demographic profile of urolithiasis in Iran: a nationwide epidemiologic study. Int Urol Nephrol 2010;42:119-126.
3.
Coker Gurkan A, Arisan S, Arisan ED, Sonmez NC, Palavan Unsal N: Association between IL-1RN VNTR, IL-1β -511 and IL-6 (-174, -572, -597) gene polymorphisms and urolithiasis. Urol Int 2013;91:220-226.
4.
Bid HK, Chaudhary H, Mittal RD: Association of vitamin-D and calcitonin receptor gene polymorphism in paediatric nephrolithiasis. Pediatr Nephrol 2005;20:773-776.
5.
Chen WC, Wu HC, Lu HF, Chen HY, Tsai FJ: Calcitonin receptor gene polymorphism: a possible genetic marker for patients with calcium oxalate stones. Eur Urol 2001;39:716-719.
6.
Lin Y, Mao Q, Zheng X, Chen H, Yang K, Xie L: Vitamin D receptor genetic polymorphisms and the risk of urolithiasis: a meta-analysis. Urol Int 2011;86:249-255.
7.
Copp DH, Cameron EC, Cheney BA, Davidson AG, Henze KG: Evidence for calcitonin - a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962;70:638-649.
8.
Carney SL: Calcitonin and human renal calcium and electrolyte transport. Miner Electrolyte Metab 1997;23:43-47.
9.
Masi L, Becherini L, Colli E, Gennari L, Mansani R, Falchetti A, Becorpi AM, Cepollaro C, Gonnelli S, Tanini A, Brandi ML: Polymorphisms of the calcitonin receptor gene are associated with bone mineral density in postmenopausal Italian women. Biochem Biophys Res Commun 1998;248:190-195.
10.
Nakamura M, Morimoto S, Zhang Z, Utsunomiya H, Inagami T, Ogihara T, Kakudo K: Calcitonin receptor gene polymorphism in Japanese women: correlation with body mass and bone mineral density. Calcif Tissue Int 2001;68:211-215.
11.
Braga V, Sangalli A, Malerba G, Mottes M, Mirandola S, Gatti D, Rossini M, Zamboni M, Adami S: Relationship among VDR (BsmI and FokI), COLIA1, and CTR polymorphisms with bone mass, bone turnover markers, and sex hormones in men. Calcif Tissue Int 2002;70:457-462.
12.
Zhao HY, Liu JM, Ning G, Zhang LZ, Jiang L, Dai M, Xu MY, Chen JL: Association of calcitonin receptor gene polymorphism with bone mineral density in Shanghai women (in Chinese). Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2003;25:258-261.
13.
Drews K, Seremak-Mrozikiewicz A, Bartkowiak-Wieczorek J, Pienkowski W, Dubiel M, Mrozikiewicz PM: Genetic polymorphism of the calcitonin receptor gene and bone mineral density in Polish population of postmenopausal women (in Polish). Ginekol Pol 2005;76:612-618.
14.
Mittal RD, Bid HK, Kumar R, Kumar A, Bhandari M: Is calcitonin receptor gene (CTR) polymorphism an appropriate marker for calcium oxalate urolithiasis? Int J Hum Genet 2004;4:57.
15.
Wolfe LA 3rd, Fling ME, Xue Z, Armour S, Kerner SA, Way J, Rimele T, Cox RF: In vitro characterization of a human calcitonin receptor gene polymorphism. Mutat Res 2003;522:93-105.
16.
Basiri A, Shakhssalim N, Houshmand M, Kashi AH, Azadvari M, Golestan B, Mohammadi Pargoo E, Pakmanesh H: Coding region analysis of vitamin D receptor gene and its association with active calcium stone disease. Urol Res 2012;40:35-40.
17.
Shakhssalim N, Kazemi B, Basiri A, Houshmand M, Pakmanesh H, Golestan B, Eilanjegh AF, Kashi AH, Kilani M, Azadvari M: Association between calcium-sensing receptor gene polymorphisms and recurrent calcium kidney stone disease: a comprehensive gene analysis. Scand J Urol Nephrol 2010;44:406-412.
18.
den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet 2001;109:121-124.
19.
Zwarts KY, Clee SM, Zwinderman AH, Engert JC, Singaraja R, Loubser O, James E, Roomp K, Hudson TJ, Jukema JW, Kastelein JJ, Hayden MR: ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet 2002;61:115-125.
20.
Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, Ruidavets JB, Luc G, Bara L, Parra HJ, Poirier O, Cambien F: Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest 1998;28:59-66.
21.
Lee HJ, Kim SY, Kim GS, Hwang JY, Kim YJ, Jeong B, Kim TH, Park EK, Lee SH, Kim HL, Koh JM, Lee JY: Fracture, bone mineral density, and the effects of calcitonin receptor gene in postmenopausal Koreans. Osteoporos Int 2010;21:1351-1360.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.